Boston Scientific Corp. Hits New 52-Week Low at $43.90

Boston Scientific Corp. has reached a significant milestone by touching a new 52-week low of USD 43.90 on June 25, 2026. This decline marks a notable downturn for the company, which has experienced a 1-year performance drop of 42.91%. In contrast, the S&P 500 has shown a positive performance of 20.77% during the same period, highlighting the challenges faced by Boston Scientific in the current market environment. The company operates within the retailing industry and boasts a market capitalization of USD 120,852 million, categorizing it as a large-cap entity. Financial metrics reveal a price-to-earnings (P/E) ratio of 36.00, indicating the market's valuation of its earnings. Additionally, Boston Scientific has a debt-to-equity ratio of 0.39, suggesting a relatively low level of debt compared to its equity. The return on equity stands at 13.88%, while the price-to-book ratio is recorded at 4.99. These figures provide insight into the company's financial health amidst its recent stock performance.